Prospective evAluatIon foR inhalation devices in Greek patients with COPD and asthma: The PAIR study.
Pulm Pharmacol Ther
; 60: 101882, 2020 02.
Article
em En
| MEDLINE
| ID: mdl-31881275
ABSTRACT
INTRODUCTION:
Chronic obstructive pulmonary disease (COPD) and asthma remain a major health burden. Adherence to inhaled therapy is critical in order to optimize treatment effectiveness. Properly designed questionnaires can assess patients' satisfaction with their inhaler devices. PATIENTS ANDMETHODS:
A total of 766 patients with COPD, asthma or Asthma-COPD Overlap (ACO) were initially enrolled. During their first visit, patients were classified into three groups (Diskus™, Elpenhaler®, Turbuhaler®). Patients completed the FSI-10 questionnaire on Day 0 and Day 60. Test-retest reliability was evaluated.RESULTS:
A total of 705 patients completed the study. FSI-10 questionnaire had good test-retest reliability (Total Intraclass Correlation Coefficient 0.86). All dry powder inhaler (DPIs) yielded satisfactory results. Median score of FSI-10 questionnaire in first visit (FSI-10-I) was significantly higher for patients receiving Elpenhaler® (45, 95% CI 44 to 46) than patients receiving Diskus™ (42, 95% CI 41 to 43) and Turbuhaler® (42, 95% CI 41 to 43) (pâ¯<â¯0.001). Accordingly, median score of FSI-10 questionnaire in the final visit (FSI-10-II) was significantly higher for patients receiving Elpenhaler® (46, 95% CI 45 to 47) than patients receiving Diskus™ (42, 95% CI 41 to 43) and Turbuhaler® (43, 95% CI 42 to 44) (pâ¯<â¯0.001).CONCLUSION:
FSI-10 questionnaire had good test-retest reliability and thus can be used in the follow-up of patients with COPD, asthma and ACO. All DPIs were highly acceptable among all study groups. Elpenhaler® achieved significantly higher ratings than Diskus™ and Turbuhaler® in FSI-10 score and presented higher preference among patients with obstructive lung diseases.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Asma
/
Sistemas de Liberação de Medicamentos
/
Antiasmáticos
/
Doença Pulmonar Obstrutiva Crônica
/
Inaladores de Pó Seco
Tipo de estudo:
Clinical_trials
/
Observational_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Pulm Pharmacol Ther
Assunto da revista:
FARMACOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Grécia